COST-EFFECTIVENESS OF HEPATITIS-A PREVENTION IN FRANCE

被引：16

作者：

SEVERO, CA

FAGNANI, F

LAFUMA, A

机构：

[1] CEMKA, Cachan, 94230

来源：

PHARMACOECONOMICS | 1995年 / 8卷 / 01期

关键词：

D O I：

10.2165/00019053-199508010-00007

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

A spreadsheet simulation model of hepatitis A disease was developed to evaluate the cost effectiveness of a recombinant hepatitis A vaccine ('Havrix', SmithKline Beecham) in high risk groups in France. Gammaglobulin prophylaxis, systematic vaccination without screening and vaccination of nonimmune persons after systematic screening were compared with the reference situation of no prevention over a 10-year period. It was found that both vaccination strategies would prevent 98% of new cases of hepatitis A, and would generate savings of FF4.2 to FF4.7 million ($US1 = FF5, 1995) in alternative service volunteers [initial seroprevalence (IS) 26%] stationed in countries with high hepatitis A endemicity. The cost per symptomatic case avoided [i.e. the cost-effectiveness ratio (CER)] was found to vary from FF177 612 with screening to FF281 463 without screening in adult tourists (IS 77%). In hospital workers, screening before vaccination (CER = FF65 108) would be about half as costly as systematic vaccination (IS 55 to 79%). Recommendations for vaccination should take into account the specific collective or individual risk, age, seroprevalence and probability of compliance with the prevention protocol.

引用

页码：46 / 61

页数：16

共 34 条

[1]

Joussemet M., Bourin P., Buisson Y., Et al., Diminution du taux de prévalence des anticorps anti-HVA chez les jeunes militaires de 20 ans, Bull Epidemiol Hebd, 28, pp. 1-3, (1991)

[2]

Wiedermann G., Ambrosch F., Kollaritsch H., Et al., Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers, Vaccine, 8, (1990)

[3]

Innis B.L., Snitbhan R., Kunasol P., Et al., Field efficacy trial of inactivated hepatitis A vaccine among children in Thailand [abstract], Vaccine, 10, (1992)

[4]

Tilzey A.J., Palmor S.J., Barrow S., Et al., Clinical trial with inactivated hepatitis A vaccine and recommendations for its use, BMJ, 304, (1992)

[5]

Tormans G., Van Damme P., Van Doorslaer E., Cost-effectiveness analysis of hepatitis A prevention in travellers, Vaccine, 10, pp. 88-92, (1992)

[6]

Chossegros P., Chevallier P., Ritter J., Et al., Coût en France des hépatites A aiguës de l’ adulte, Presse Med, 23, (1994)

[7]

Rapport annuel: 1990, 8, pp. 75-88, (1991)

[8]

Levy S., Rouanet de Berchoux P., Evaluation du coû en volume de la transplantation hépatique, Mémoire du DESS d’Economie et Gestion des Systèmes de Santé, 1990-1991, (1991)

[9]

Hadler S.C., Global impact of hepatitis A virus infection: changing patterns, Viral hepatitis and liver disease, pp. 14-20, (1991)

[10]

Lednar W.M., Lemon S.M., Kirkpatrick J.W., Et al., Frequency of illness associated with epidemic hepatitis A virus infections in adults, Am J Epidemiol, 122, (1985)

← 1 2 3 4 →